Cited by 399Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia

Jicha, Gregory A., Parisi, Joseph E., Dickson, Dennis W., Johnson, Kris, Cha, Ruth, Ivnik, Robert J., Tangalos, Eric G., Boeve, Bradley F. +3 more·2006·Archives of Neurology

Abstract

BACKGROUND: The pathologic outcome of patients diagnosed with mild cognitive impairment (MCI) following progression to dementia is poorly understood. OBJECTIVE: To determine the pathologic substrates of dementia in cases with prior diagnosis of amnestic MCI. DESIGN AND SETTING: Community-based cohort. PATIENTS: Thirty-four subjects followed up prospectively as part of a community-based study who were diagnosed with amnestic MCI, progressed to clinical dementia, and underwent subsequent postmortem brain analysis. MAIN OUTCOME MEASURES: Neuropathologic analyses resulted in assignment of a primary pathologic diagnosis and included staging of Alzheimer pathologic abnormalities and identification of contributing vascular disease, Lewy bodies, and argyrophilic grains. RESULTS: Although the majority of subjects progressed both clinically and pathologically to Alzheimer disease (AD), 10 (29%) of them developed non-AD primary pathologic abnormalities. All of the cases were found to have sufficient pathologic abnormalities in mesial temporal lobe structures to account for their amnestic symptoms regardless of the cause. Most subjects were found to have secondary contributing pathologic abnormalities in addition to primary pathologic diagnoses. No significant differences between subjects with and without neuropathologically proven AD were detected in demographic variables, apolipoprotein E genotype, or cognitive test measures at onset of MCI, onset of dementia, or last clinical evaluation. CONCLUSIONS: The neuropathologic outcome of amnestic MCI following progression to dementia is heterogeneous, and it includes AD at a high frequency. Complex neuropathologic findings including 2 or more distinct pathologic entities contributing to dementia may be common in community-based cohorts. Neither demographic variables nor cognitive measures had predictive value in determining which patients diagnosed with MCI will develop the neuropathologic features of AD.

Integrity signals

Registry

Crossref · 10.1001/archneur.63.5.674

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Those with amnestic mild cognitive impairment do not always have AD at autopsy even though they have a reported risk for developing dementia of 10-15%, and sometimes they do not have any discernable pathology at autopsy.

    “Those with amnestic mild cognitive impairment do not always have AD at autopsy even though they have a reported risk for developing dementia of 10–15%, and sometimes they do not have any discernable pathology at autopsy [145, 146].”

    From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [145]

The citation lists haven’t been fetched yet

References 48 · Cited by 399

Authors
Jicha, G. A., Parisi, J. E., Dickson, D. W., Johnson, K., Cha, R., Ivnik, R. J., Tangalos, E. G., Boeve, B. F., Knopman, D. S., Braak, H., & Petersen, R. C.
Affiliations
  • Mayo Clinic (US)
  • Goethe University Frankfurt (DE)
Venue
Archives of Neurology
Published
2006-05-01
Volume
63
Issue
5
Pages
674
ISSN
0003-9942 (ISSN-L)
OpenAlex
W2006247983
Cited by
399
References
48
Citations by year
2026: 5 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 4 · 2021: 13 · 2020: 12 · 2019: 18 · 2018: 19 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 24 · 2013: 31 · 2012: 31
FWCI
23.85
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P50‐AG16574, U01AG06786, AG 16574, U01AG006786, P50AG016574)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
mild cognitive impairment, amnestic MCI, dementia progression, Alzheimer's disease, neuropathology, medial temporal lobe, vascular dementia, Lewy bodies, argyrophilic grains, apolipoprotein E
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Dementia, Demography, Female, Humans, Longitudinal Studies, Male, Neurologic Examination, Neuropsychological Tests, Postmortem Changes, Prognosis, Residence Characteristics, Retrospective Studies, Cohort Studies, Geriatric Assessment, Case-Control Studies, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review